Drs Brinton and Michos highlight LDL-C apheresis in the treatment landscape for homozygous familial hypercholesterolemia [HoFH]. Eliot Brinton, MD: What do we do if the standard treatments don’t work?

Regeneron and Sanofi announced positive data from ODYSSEY ESCAPE, a Phase 3 study which evaluated Praluent (alirocumab) in patients with heterozygous familial hypercholesterolemia (HeFH) requiring ...

It has previously been shown that a single LDL apheresis can markedly reduce CRP in hyperlipidemic patients and biweekly treatment can lower CRP over a period of six months in a small group of ...

Familial hypercholesterolemia is an autosomal dominant disorder resulting in severe elevation of total and LDL cholesterol due to defective hepatic LDL receptor. Heterozygotes occur in about 1 of 500 ...

Lipoprotein apheresis, a therapy normally used to filter excess cholesterol from the blood of patients with familial hypercholesterolemia, may have a new role in patients with refractory angina. New ...

Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB: SIGY), a developer of dialysis-like therapies to address cardiovascular disease and cancer, today released a note authored by inventor and ...

Using apheresis to remove a serum protein called soluble Fms-like tyrosine kinase-1 (Sflt-1) may help pregnant women with severe preeclampsia safely delay delivery, according to a pilot study ...

Patients who have heterozygous familial hypercholesterolemia (HeFH), a condition that causes abnormally raised low-density lipoprotein cholesterol (LDL-C) levels and premature cardiovascular disease, ...

Cardiac allograft vasculopathy (CAV) is associated with poor outcomes in heart transplant recipients. As elevated levels of blood compounds, including cholesterol, C-reactive protein and fibrinogen, ...

The global apheresis market is expected to grow at a CAGR of ~8% during the forecast period. The market expansion is driven by the increasing prevalence of chronic and autoimmune diseases, growing ...

Rome, Italy – 29 August, 2016: Lipoprotein apheresis, a therapy normally used to filter excess cholesterol from the blood of patients with familial hypercholesterolemia, may have a new role in ...